IN2013CN09704A - - Google Patents
Info
- Publication number
- IN2013CN09704A IN2013CN09704A IN9704CHN2013A IN2013CN09704A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A IN 9704CHN2013 A IN9704CHN2013 A IN 9704CHN2013A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A
- Authority
- IN
- India
- Prior art keywords
- mirabegron
- preparation
- form crystal
- amorphous
- aspects
- Prior art date
Links
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 abstract 3
- 229960001551 mirabegron Drugs 0.000 abstract 3
- 239000013078 crystal Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Plural Heterocyclic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Liquid Crystal Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN9704CHN2013 IN2013CN09704A (fr) | 2011-05-18 | 2012-05-17 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1678CH2011 | 2011-05-18 | ||
| US201161502911P | 2011-06-30 | 2011-06-30 | |
| IN9704CHN2013 IN2013CN09704A (fr) | 2011-05-18 | 2012-05-17 | |
| PCT/IN2012/000356 WO2012156998A2 (fr) | 2011-05-18 | 2012-05-17 | Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013CN09704A true IN2013CN09704A (fr) | 2015-07-03 |
Family
ID=47177412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9704CHN2013 IN2013CN09704A (fr) | 2011-05-18 | 2012-05-17 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9283210B2 (fr) |
| EP (1) | EP2709993A4 (fr) |
| IN (1) | IN2013CN09704A (fr) |
| WO (1) | WO2012156998A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655885B2 (en) * | 2011-05-18 | 2017-05-23 | Dr. Reddy's Laboratories Ltd. | Amorphous mirabegron and processes for crystal forms of mirabegron |
| CN103193730A (zh) * | 2013-04-17 | 2013-07-10 | 苏州永健生物医药有限公司 | 一种米拉贝隆的合成方法 |
| WO2015040605A1 (fr) | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Forme cristalline de mirabegron |
| WO2015040573A1 (fr) | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Solvate mirabegron diméthyl-sulfoxyde et son utilisation pour le traitement de l'hyperactivité vésicale |
| WO2015044965A1 (fr) | 2013-09-30 | 2015-04-02 | Megafine Pharma (P) Ltd. | Procédé de préparation du mirabégron et de sa forme alpha cristalline |
| ITMI20131653A1 (it) | 2013-10-07 | 2015-04-08 | Dipharma Francis Srl | Forme cristalline di un agonista adrenergico |
| WO2016049749A1 (fr) * | 2014-10-01 | 2016-04-07 | Apotex Inc. | Formes solides du mirabégron |
| EP3253741A1 (fr) | 2015-02-02 | 2017-12-13 | Lupin Limited | Procédé pour la préparation de forme polymorphe de mirabegron |
| US10253005B2 (en) * | 2015-05-11 | 2019-04-09 | Aurobindo Pharma Ltd. | Process for the preparation of Mirabegron alpha-form crystals |
| JP6618736B2 (ja) * | 2015-09-01 | 2019-12-11 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
| FR3043555B1 (fr) * | 2015-11-17 | 2019-10-25 | Centre National De La Recherche Scientifique (Cnrs) | Mirabegron pour le traitement de maladies retiniennes |
| EP3184516A1 (fr) | 2015-12-23 | 2017-06-28 | Enantia, S.L. | Complexe d'inclusion crystallin de mirabegron avec beta-cyclodextrine |
| KR101937713B1 (ko) * | 2017-07-14 | 2019-01-14 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
| KR101928987B1 (ko) * | 2018-08-28 | 2018-12-13 | (주) 성운파마코피아 | 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도 |
| CN110590699B (zh) * | 2019-09-29 | 2022-11-15 | 广东先强药业有限公司 | 一种米拉贝隆的精制方法 |
| CN112745276B (zh) * | 2019-10-31 | 2023-10-03 | 四川国为制药有限公司 | 一种米拉贝隆的结晶方法 |
| US11583521B2 (en) * | 2020-07-01 | 2023-02-21 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
| CN114539182B (zh) * | 2020-11-24 | 2024-08-09 | 威智医药股份有限公司 | 转晶溶剂及其应用和米拉贝隆α晶型的制备方法 |
| KR102333167B1 (ko) | 2021-05-26 | 2021-12-01 | 유니셀랩 주식회사 | 효율적이고 대량생산이 가능한 미라베그론 무정형 제조방법 |
| CN113773274A (zh) * | 2021-08-09 | 2021-12-10 | 石药集团中奇制药技术（石家庄）有限公司 | 一种米拉贝隆α晶型原料的重结晶方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE266639T1 (de) | 1997-10-17 | 2004-05-15 | Yamanouchi Pharma Co Ltd | Amidderivate oder deren salze |
| US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| USRE44872E1 (en) | 2002-11-07 | 2014-04-29 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
-
2012
- 2012-05-17 EP EP12785575.7A patent/EP2709993A4/fr not_active Withdrawn
- 2012-05-17 US US14/117,569 patent/US9283210B2/en not_active Expired - Fee Related
- 2012-05-17 IN IN9704CHN2013 patent/IN2013CN09704A/en unknown
- 2012-05-17 WO PCT/IN2012/000356 patent/WO2012156998A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012156998A2 (fr) | 2012-11-22 |
| US9283210B2 (en) | 2016-03-15 |
| EP2709993A2 (fr) | 2014-03-26 |
| US20140206729A1 (en) | 2014-07-24 |
| WO2012156998A3 (fr) | 2013-01-17 |
| EP2709993A4 (fr) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2013CN09704A (fr) | ||
| PL2744768T3 (pl) | Sposób wytwarzania klinkieru zawierającego ternezyt | |
| IL230030B (en) | Recombinant microorganism for the production of useful metabolites | |
| GEP20247677B (en) | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | |
| MX2015005891A (es) | Formas polimórficas de suvorexant. | |
| IN2015KN00262A (fr) | ||
| EA029539B8 (ru) | Фармацевтическая композиция ситаглиптина | |
| PL2785701T3 (pl) | Krystaliczna postać kabazytakselu i sposób jej otrzymywania | |
| HUP1100701A2 (en) | Novel process for the preparation of travoprost | |
| SG11201402949RA (en) | Process for producing nutrient composition | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| IL229647A0 (en) | A new process for the preparation of prostaglandin amides | |
| WO2014068586A3 (fr) | Compositions orales solides de tolvaptan | |
| WO2012131707A3 (fr) | Nouvelle forme cristalline de bortezomib, son procédé de préparation et composition pharmaceutique l'utilisant | |
| EP4289819A3 (fr) | Procédé de préparation de 3-aminopipéridine enrichie sous la forme énantiomère | |
| EP2671847A4 (fr) | Procédé de fabrication d'un verre à luminophore dispersé et verre à luminophore dispersé | |
| ZA201404385B (en) | Process for the manufacture of ferrochrome | |
| IN2014DN09451A (fr) | ||
| MX2012010443A (es) | Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos. | |
| MX2014009015A (es) | Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma. | |
| WO2014102759A3 (fr) | Procédé de préparation de dasatinib et de ses intermédiaires | |
| HUP1100177A2 (en) | Recycled composition and process for preparation of it and production of regenarated, vulcanised gum | |
| WO2013046233A3 (fr) | Procédé de préparation d'acétate d'octréotide | |
| IN2013CH05282A (fr) | ||
| EP2694621B8 (fr) | Procédés utilisables en vue de la production de carburant |